Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...
The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The watchdog blocked access to DeepSeek after the companies ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The Food and Drug Administration on Tuesday approved Journavx, the first drug in a new class of non-opioid pain medications, ...
The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid ...
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback